Online citations, reference lists, and bibliographies.
← Back to Search

Molecular Markers For Bladder Cancer: The Road To A Multimarker Approach

M. Birkhahn, A. P. Mitra, R. Cote
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Bladder cancer is the seventh most common malignancy worldwide, with almost 14,000 patients dying from this disease in the USA alone. Because of the need for long-term and frequent follow-up, as well as the paucity of sensitive and specific noninvasive tests, bladder cancer management has the highest cost per patient among all cancer types. Several molecular markers, especially members of the cell cycle regulation and apoptosis pathways, have been investigated. However, no individual marker has been prognostically powerful enough to change clinical management. The combined analysis of a panel of markers spanning different pathways is the most promising approach. We give an overview of the most important molecular markers functioning in crucial pathways and focus on their role in multimarker analysis.
This paper references
Evaluation of p21 WAF1/CIP1 and cyclin D 1 expression in the progression of superficial bladder cancer. Finbladder Group
T Liukkonen (2000)
10.1073/PNAS.96.12.6937
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.
W. Tao (1999)
10.1016/S0022-5347(01)62001-9
p53 and RB expression predict progression in T1 bladder cancer.
H. Grossman (1998)
10.1056/NEJM199411103311903
Accumulation of nuclear p53 and tumor progression in bladder cancer.
D. Esrig (1994)
10.1016/J.EURURO.2004.10.006
Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients.
W. Liu (2005)
10.1038/modpathol.3800757
Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness
S. Shariat (2007)
p150 is a p53-independent regulator of p21
D Li (2004)
10.1046/j.1464-410x.1999.00871.x
Apoptosis and its clinical significance for bladder cancer therapy
J. Kelly (1999)
10.1126/SCIENCE.1905840
p53 mutations in human cancers.
M. Hollstein (1991)
The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology 67(3 Suppl
AJ Carmack (2006)
10.1016/S0302-2838(01)00038-0
p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
Andrés Rodríguez-Alonso (2002)
10.1309/LTFU-3UUM-BY09-5HUM
Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
A. Lopez-Beltran (2004)
10.1016/S0360-3016(00)01503-0
Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
L. Moonen (2001)
10.1159/000078807
Expression Patterns of Cyclins D1, E and Cyclin-Dependent Kinase Inhibitors p21(Waf1/Cip1) and p27(Kip1) in Urothelial Carcinoma: Correlation with Other Cell-Cycle-Related Proteins (Rb, p53, Ki-67 and PCNA) and Clinicopathological Features
E. Ioachim (2004)
10.1016/0092-8674(92)90243-6
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Laura R. Livingstone (1992)
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
T. Miyashita (1994)
10.1016/S0022-5347(17)53725-8
Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.
W. Lutzeyer (1982)
10.1200/JCO.2004.05.174
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
S. Chatterjee (2004)
Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
A. Pollack (1997)
10.1016/S1470-2045(05)70315-6
P53 as a prognostic marker for bladder cancer: a meta-analysis and review.
N. Malats (2005)
10.1158/1078-0432.CCR-07-0013
A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer
M. Sánchez-Carbayo (2007)
10.1126/science.272.5263.877
Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
S. Coats (1996)
Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
M. Migaldi (2000)
10.1016/S0092-8674(00)81401-4
ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways
Y. Zhang (1998)
10.1016/S0027-5107(03)00133-7
Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors.
G. Domínguez (2003)
10.1158/1055-9965.EPI-04-0404
Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer
E. Gorelik (2005)
10.1038/sj.onc.1205304
Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer
R. Simon (2002)
10.1111/j.1742-1241.2006.01105.x
Expression patterns of cyclins D1, E and cyclin‐dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki‐67 and PCNA) and clinicopathological features
E. Ioachim (2008)
10.1016/0092-8674(94)90572-X
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
K. Polyak (1994)
10.1159/000020364
p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer
B. Schmitz-Dräger (2000)
10.1016/J.JURO.2006.07.132
Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
A. Lamy (2006)
10.1016/S0022-5347(05)66332-X
Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
A. Haitel (2001)
10.1093/JNCI/90.14.1072
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.
J. Stein (1998)
10.1126/SCIENCE.275.5303.1132
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
R. Kluck (1997)
Decreasing of p27 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer
T Kamai (2001)
10.1016/S0168-9525(00)89010-1
Regulators of cell death.
S. Korsmeyer (1995)
10.1016/S1470-2045(07)70002-5
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
J. Karam (2007)
10.1007/s002400000116
Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer
T. Liukkonen (2000)
10.1093/JNCI/84.16.1251
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.
C. Cordon-Cardo (1992)
10.1016/S0092-8674(00)81683-9
The Hallmarks of Cancer
D. Hanahan (2000)
10.1038/bjc.1991.269
Drug-target interactions: only the first step in the commitment to a programmed cell death?
C. Dive (1991)
10.1016/J.EURURO.2005.12.041
The Predictive Value of p53, p27Kip1, and α-Catenin for Progression in Superficial Bladder Carcinoma
B. Schrier (2006)
10.1007/s00240-002-0274-1
Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications
I. Giannopoulou (2002)
10.1007/s00240-002-0263-4
Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells
Sheau-Yun Yuan (2002)
10.1038/sj.onc.1209608
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S. Fulda (2006)
10.1016/J.JSS.2007.01.012
Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
R. Bartoletti (2007)
10.1016/S0090-4295(00)00678-6
Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma.
K. H. Franke (2000)
10.1016/S0022-5347(01)62456-X
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.
R. Cote (1998)
10.1038/nature01511
Mass spectrometry-based proteomics
R. Aebersold (2003)
10.1038/358015A0
p53, guardian of the genome
D. Lane (1992)
10.1046/J.1464-410X.1998.00628.X
The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.
P. Allard (1998)
10.1038/nrc968
Validating survivin as a cancer therapeutic target
D. Altieri (2003)
10.1016/J.EURURO.2003.11.011
Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).
A. Lopez-Beltran (2004)
10.1016/S0167-7799(01)01639-0
Proteomics: a technology-driven and technology-limited discovery science.
K. Lee (2001)
10.1016/S1078-1439(03)00176-5
The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
T. Tzai (2004)
10.1002/path.1952
Cyclin D3 expression in primary Ta/T1 bladder cancer
A. Lopez-Beltran (2006)
• Study demonstrating that Rb hyperphosphorylation is responsible for patients with high Rb immunoreactivity having a prognosis identical to those with a mutated gene
•• Study demonstrating the cooperative effect of apoptotic markers in bladder cancer
Mass spectrometrybased proteomics
R Aebersold (2003)
10.1016/S0002-9440(10)64592-0
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer.
J. Richter (2000)
10.1038/25867
p14ARF links the tumour suppressors RB and p53
S. Bates (1998)
10.1093/JNCI/84.16.1256
Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.
C. Logothetis (1992)
10.1016/J.CANLET.2005.05.039
Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
H. Cho (2006)
10.1007/s00432-006-0123-7
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer
F. Galmozzi (2006)
10.1200/JCO.2006.08.2073
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
A. P. Mitra (2006)
10.1016/S0302-2838(02)00003-9
Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival.
P. Korkolopoulou (2002)
10.1016/J.EURURO.2006.07.023
Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.
I. Schultz (2007)
10.1002/path.1567
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer
S. Chatterjee (2004)
10.1016/J.CANLET.2006.10.011
BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
R. González‐Cámpora (2007)
10.1002/jcp.10327
Survivin study: What is the next wave?
F. Li (2003)
10.1046/j.1464-410x.2000.00612.x
Bcl‐2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
P. W. Cooke (2000)
•• Study indicating that high Rb expression may reflect a dysfunctional Rb pathway
•• Study demonstrating that p53 alterations can be beneficial for cisplatin-based adjuvant chemotherapy
10.1111/j.1349-7006.1998.tb03276.x
Expression of G1→S Transition Regulatory Molecules in Human Urothelial Cancer
M. Oya (1998)
10.1016/J.UROLOGY.2006.01.026
The diagnosis and staging of bladder cancer: from RBCs to TURs.
A. Carmack (2006)
10.1128/MCB.24.9.3885-3893.2004
p150Sal2 Is a p53-Independent Regulator of p21WAF1/CIP
D. Li (2004)
10.1200/JCO.2004.03.118
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
S. Shariat (2004)
10.1200/JCO.2004.01.035
Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer.
A. Osoegawa (2004)
10.3322/canjclin.57.1.43
Cancer Statistics, 2007
A. Jemal (2007)
10.1016/S0360-3016(98)00472-6
Apoptosis in carcinoma of the bladder: relation with radiation treatment results.
P. Lara (1999)
10.1038/385123B0
p53 and treatment of bladder cancer
R. Cote (1997)
10.1038/381713A0
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
T. Waldman (1996)
10.1016/0092-8674(91)90557-F
The E2F transcription factor is a cellular target for the RB protein
S. Chellappan (1991)
10.1016/J.CANLET.2006.12.020
Survivin: a promising tumor biomarker.
M. Duffy (2007)
Effect of p21 expression on tumor progression in bladder cancer
JP Stein (1998)
10.4103/0019-5359.16298
Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer.
Y. Wu (2005)
10.1016/J.HUMPATH.2006.05.017
Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
S. Shariat (2006)
10.1200/JCO.2005.03.2375
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
M. Sánchez-Carbayo (2006)
10.1016/J.JURO.2007.05.160
Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
K. Steven (2007)
10.1046/j.1442-2042.2000.00212.x
Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor
Y. Takagi (2000)
Epub ahead of print)
(2007)
10.1056/NEJM199803263381312
The CDKN2A tumor-suppressor locus--a tale of two proteins.
B. Clurman (1998)
p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP).
D. Li (2004)
10.1016/S0022-5347(17)58916-8
Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.
A. Althausen (1976)
10.1016/0360-3016(96)00089-2
Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer.
V. Chyle (1996)
10.1002/ijc.10055
Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle‐associated proteins, cell proliferation and clinical outcome
A. Sgambato (2002)
10.1002/cncr.20200
p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approach
Xavier Garcia del Muro (2004)
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
D. Evans (1994)
Decreasing of p27 Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer
T Kamai (2001)
10.1136/jcp.49.5.395
Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
H. Shiina (1996)
10.1158/1078-0432.CCR-07-0109
Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer
A. B. Als (2007)
10.1016/J.BBRC.2005.11.072
p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
K. Kawamoto (2006)
10.1309/ltfu3uumby095hum
Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors
A. Lopez-Beltran (2004)



This paper is referenced by
10.3109/00365590903296837
Combinations of urine-based tumour markers in bladder cancer surveillance
M. Horstmann (2009)
Chapter 5 A new generation of optical diagnostics for bladder cancer : technology , diagnostic accuracy and future applications
E. Cauberg (2011)
10.1016/j.eururo.2009.09.013
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
M. Birkhahn (2010)
10.1007/978-3-319-64769-2
Precision Molecular Pathology of Bladder Cancer
D. Hansel (2018)
10.1007/978-3-319-93339-9
Genitourinary Cancers
S. Daneshmand (2018)
10.1016/j.critrevonc.2013.08.008
Biomarkers in bladder cancer: translational and clinical implications.
L. Cheng (2014)
10.1158/1078-0432.CCR-17-3783
Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer
Hyunjin Park (2018)
10.1016/j.urolonc.2010.03.012
New concepts of biobanks--strategic chance for uro-oncology.
P. Goebell (2010)
10.3389/fonc.2020.00459
Preoperative Prediction of Extramural Venous Invasion in Rectal Cancer: Comparison of the Diagnostic Efficacy of Radiomics Models and Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Xiangling Yu (2020)
10.1007/s00345-008-0357-x
Molecular targets and targeted therapies in bladder cancer management
R. Youssef (2008)
10.1007/978-3-319-64769-2_1
Risk Factors and Molecular Features Associated with Bladder Cancer Development
A. P. Mitra (2018)
10.1093/jnci/dju290
Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer
A. P. Mitra (2014)
10.1177/1756287216638981
Molecular substratification of bladder cancer: moving towards individualized patient management
A. P. Mitra (2016)
10.1097/PAP.0b013e318199f89e
Utility of Diagnostic and Prognostic Markers in Urothelial Carcinoma of the Bladder
Joshua F. Coleman (2009)
10.1016/j.ejca.2013.04.033
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine.
M. Birkhahn (2013)
10.1371/journal.pone.0045967
Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer
I. Gromova (2012)
10.1111/j.1464-410X.2009.08674.x
A novel strategy based on histological protein profiling in‐silico for identifying potential biomarkers in urinary bladder cancer
M. U. Segersten (2009)
10.1007/s00261-020-02495-6
Using texture analysis as a predictive factor of subtype, grade and stage of renal cell carcinoma
Servan Yaşar (2020)
10.3389/fonc.2019.01548
Multiple Level CT Radiomics Features Preoperatively Predict Lymph Node Metastasis in Esophageal Cancer: A Multicentre Retrospective Study
L. Wu (2019)
10.1097/MOU.0b013e328356ade6
Pathological possibilities and pitfalls in detecting aggressive bladder cancer
A. P. Mitra (2012)
10.1016/j.preghy.2020.04.011
Nomogram-based prediction of pre-eclampsia in the first trimester of gestation.
W. Wang (2020)
10.21037/amj.2020.02.06
Role and efficacy of current biomarkers in bladder cancer
A. Giordano (2020)
10.1002/jmri.27101
Multiparametric MRI-Based Radiomics Nomogram for Predicting Lymph Node Metastasis in Early-Stage Cervical Cancer.
Meiling Xiao (2020)
10.1186/1746-1596-8-111
Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma
A. Zizzi (2013)
10.1586/erm.10.110
Systematic antibody and antigen-based proteomic profiling with microarrays
B. Ayoglu (2011)
10.3389/fbioe.2020.00206
Predicting the Risk of Melanoma Metastasis Using an Immune Risk Score in the Melanoma Cohort
Y. Sheng (2020)
10.1016/j.eururo.2009.02.033
A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications.
E. Cauberg (2009)
10.1016/J.EURURO.2009.09.040
Reply from Authors re: Joseph L. Chin. In Search of the Perfect Crystal Ball for Ta Urothelial Cancer. Eur Urol 2010;57:21–2
A. P. Mitra (2010)
10.1007/s13167-018-0149-3
Radiomics improves efficiency for differentiating subclinical pheochromocytoma from lipid-poor adenoma: a predictive, preventive and personalized medical approach in adrenal incidentalomas
X. Yi (2018)
Potential Role for Targeted Therapy in Muscle-Invasive Bladder Cancer from the Cancer Genome
A. P. Mitra (2015)
10.1016/j.eururo.2009.02.039
Editorial comment on: A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications.
R. Bryan (2009)
10.1016/j.acra.2019.12.007
Deep Learning Features Improve the Performance of a Radiomics Signature for Predicting KRAS Status in Patients with Colorectal Cancer.
Xiaomei Wu (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar